Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp50 | Bone development/growth and fracture repair | ECTS2014

Forearm fracture in premenopausal women, a disorder of trabecular corticalization

Bala Yohann , Rozental Tamara , Sepehrizadeh Tara , Bouxsein Mary L , Zebaze Roger , Seeman Ego

Postmenopausal women with forearm fracture have higher cortical porosity and lower trabecular density perhaps due to excessive age-related bone loss1. Remodelling becomes unbalanced and rapid only after ~45 years of age. We therefore proposed that bone fragility in premenopausal women with a forearm fracture originates during growth. At metaphyses, trabeculae emerging from the periphery of the growth plate form cortex by ‘corticalization’)2. We ...

ba0001oc5.1 | Treatment of osteoporosis | ECTS2013

A Three-year randomized sham-controlled trial of low magnitude mechanical stimulation in an elderly sample: the ‘VIBES' trial

Kiel Douglas , Hannan Marian , Sisson Emily , Bouxsein Mary , Barton Bruce , Dewkett Dawn , Magaziner Jay , Zimmerman Sheryl , Shane Elizabeth , Leary Elizabeth Teng , Carroll Danette , Allaire Brett , Lang Thomas , Rubin Clinton

Non-pharmacologic approaches to preserve or increase BMD include whole body vibration (WBV). A meta-analysis and one-year randomized trial concluded that WBV has no effect on BMD in older women; however, previous trials were relatively brief and did not include a sham control group. Therefore, we conducted the Vibration to Improve Bone in Elderly Subjects (‘VIBES’) trial, a randomized, sham-controlled trial of 10 min of daily WBV (0.3 g at 30 Hz) in seniors recruited...

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...